Cargando…
Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled tri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ubiquity Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607635/ https://www.ncbi.nlm.nih.gov/pubmed/37901601 http://dx.doi.org/10.5334/gh.1274 |
_version_ | 1785127588339908608 |
---|---|
author | Qin, Jinlv Wang, Guizuo Han, Dong |
author_facet | Qin, Jinlv Wang, Guizuo Han, Dong |
author_sort | Qin, Jinlv |
collection | PubMed |
description | BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of PH with macitentan, compared with placebo or blank, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). RESULTS: Six RCTs (enrolling 1,003 participants) met the inclusion criteria. Macitentan showed significant effects on 6-min walk distance (6MWD) (WMD 12.06 m, 95% CI 2.12 to 21.99 m), pulmonary vascular resistance (PVR) (WMD –186.51 dyn·s/cm(–5), 95% CI –232.72 to –140.29 dyn·s/cm(–5)), mean pulmonary artery pressure (mPAP) (WMD –3.20 mmHg, 95% CI –5.93 to –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) (WMD –232.47 ng/L, 95% wCI –318.22 to –146.72 ng/L), and cardiac index (WMD 0.39 L/min/m(2), 95% CI 0.20 to 0.58 L/min/m(2)). CONCLUSION: Macitentan significantly improved 6MWD, PVR, mPAP, NT-proBNP, and cardiac index in patients with PH. Macitentan should be further validated in patients with PH. |
format | Online Article Text |
id | pubmed-10607635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Ubiquity Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106076352023-10-28 Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Qin, Jinlv Wang, Guizuo Han, Dong Glob Heart Review BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of PH with macitentan, compared with placebo or blank, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). RESULTS: Six RCTs (enrolling 1,003 participants) met the inclusion criteria. Macitentan showed significant effects on 6-min walk distance (6MWD) (WMD 12.06 m, 95% CI 2.12 to 21.99 m), pulmonary vascular resistance (PVR) (WMD –186.51 dyn·s/cm(–5), 95% CI –232.72 to –140.29 dyn·s/cm(–5)), mean pulmonary artery pressure (mPAP) (WMD –3.20 mmHg, 95% CI –5.93 to –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) (WMD –232.47 ng/L, 95% wCI –318.22 to –146.72 ng/L), and cardiac index (WMD 0.39 L/min/m(2), 95% CI 0.20 to 0.58 L/min/m(2)). CONCLUSION: Macitentan significantly improved 6MWD, PVR, mPAP, NT-proBNP, and cardiac index in patients with PH. Macitentan should be further validated in patients with PH. Ubiquity Press 2023-10-26 /pmc/articles/PMC10607635/ /pubmed/37901601 http://dx.doi.org/10.5334/gh.1274 Text en Copyright: © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Qin, Jinlv Wang, Guizuo Han, Dong Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title | Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_full | Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_fullStr | Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_short | Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_sort | benefits of macitentan in patients with pulmonary hypertension: a systematic review and meta-analysis of randomized controlled trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607635/ https://www.ncbi.nlm.nih.gov/pubmed/37901601 http://dx.doi.org/10.5334/gh.1274 |
work_keys_str_mv | AT qinjinlv benefitsofmacitentaninpatientswithpulmonaryhypertensionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT wangguizuo benefitsofmacitentaninpatientswithpulmonaryhypertensionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT handong benefitsofmacitentaninpatientswithpulmonaryhypertensionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |